Deals: Biovitrum And Santhera Sign An Exclusive License And Collaboration Agreement For The Development Of DPP-IV Inhibitors For The Treatment Of Type 2 Diabetes And Other Metabolic Diseases

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Deals review
Deal details

Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases

In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits PL Intelligence has to offer. Find out more.

Request a demo of
PL Intelligence

Debiopharm Group and Mercury Therapeutics, Inc. sign sign an exclusive license agreement for the development and commercialisation of Debio 0930 - A first-in-class, small molecule activator of AMPK fo

BIOVITRUM INDUSTRIAL PARTNER IN LEADING EUROPEAN RESEARCH COLLABORATION ON DIABETES

BIOVITRUM LICENSES A PROJECT IN METABOLIC DISEASES FROM SYNAPTIC, A WHOLLY OWNED SUBSIDIARY OF LUNDBECK

Lilly licenses oral DPP-IV inhibitor from Taisho Pharmaceutical

Medivir & Biovitrum Initiate Research Collaboration in Diabetes

Almirall signs a co-marketing agreement with MSD to commercialise in Spain a new medicine for type 2 diabetes

PPD and Syrrx in diabetes and other major diseases collaboration

ASINEX AND BIOVITRUM ANNOUNCE 3 YEAR DRUG DISCOVERY COLLABORATION

GRAFFINITY PHARMACEUTICALS AG AND MYOCONTRACT AG MERGE TO FORM SANTHERA PHARMACEUTICALS AG

Related categories

Therapeutic target

Metabolism

Diabetes type II

Industry sector

Pharmaceutical

More deals

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us

Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases

Related deals

Related categories

More deals

Latest deals

Most viewed deals

By month